India, Oct. 23 -- Drug major Johnson & Johnson (JNJ) announced Friday that its TECVAYLI (teclistamab) monotherapy has been approved by the European Commission to treat adult patients with relapsed/refractory multiple myeloma or RRMM, expanding treatment options from first relapse.
Multiple myeloma is a complex blood cancer, which affects a type of white blood cell called plasma cells, which are found in the bone marrow.
Teclistamab is an off-the-shelf or ready-to-use bispecific antibody. It is a subcutaneous injection, which redirects T-cells through two cellular targets to activate the body's immune system to fight cancer.
Teclistamab is currently being evaluated in several combination studies. So far, more than 30,700 patients have bee...